Cullen Capital Management LLC Cuts Stake in Pfizer Inc. $PFE

Cullen Capital Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 7.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,097,331 shares of the biopharmaceutical company’s stock after selling 161,356 shares during the quarter. Cullen Capital Management LLC’s holdings in Pfizer were worth $52,224,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Horizon Financial Services LLC raised its position in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the 4th quarter worth $26,000. YANKCOM Partnership purchased a new position in Pfizer during the 4th quarter worth $28,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new position in Pfizer during the 2nd quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Morgan Stanley increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Pfizer Price Performance

Shares of NYSE PFE opened at $26.19 on Friday. The stock has a market cap of $149.26 billion, a price-to-earnings ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company’s 50-day moving average price is $26.43 and its 200 day moving average price is $26.32. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s dividend payout ratio is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.